Bristol-Myers pharmaceuticals news

Bristol-Myers Squibb said it will shift its R&D to a specialty biopharma model and will discontinue its discovery work in HCV, diabetes and neuroscience. A spokesperson said the move will cut 70-75 positions in R&D, or about 1% of the pharma's R&D total workforce. BMS said it will instead continue to focus on HIV, HBV, heart failure, fibrotic disease, cancer and immunoscience and plans to increase investment in cancer immunotherapies. Bristol-Myers said it will continue with its development, regulatory and commercial plans for its late-stage pipeline. The pharma declined to disclose details. ...